Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash & Equivalents (2023 - 2025)

Contineum Therapeutics has reported Cash & Equivalents over the past 3 years, most recently at $42.6 million for Q3 2025.

  • Quarterly results put Cash & Equivalents at $42.6 million for Q3 2025, up 4.26% from a year ago — trailing twelve months through Sep 2025 was $42.6 million (up 4.26% YoY), and the annual figure for FY2024 was $21.9 million, up 41.33%.
  • Cash & Equivalents for Q3 2025 was $42.6 million at Contineum Therapeutics, up from $20.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CTNM hit a ceiling of $77.2 million in Q2 2024 and a floor of $15.5 million in Q4 2023.
  • Median Cash & Equivalents over the past 3 years was $22.2 million (2024), compared with a mean of $32.2 million.
  • Biggest five-year swings in Cash & Equivalents: soared 41.33% in 2024 and later plummeted 73.09% in 2025.
  • Contineum Therapeutics' Cash & Equivalents stood at $15.5 million in 2023, then surged by 41.33% to $21.9 million in 2024, then soared by 94.29% to $42.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $42.6 million (Q3 2025), $20.8 million (Q2 2025), and $22.5 million (Q1 2025) per Business Quant data.